1st trimester: Specific marker for pre-eclampsia - PIGF
In pregnancies that develop preeclampsia, maternal serum placental growth factor (PlGF) levels decrease significantly in the first trimester. This makes it an important biomarker used to predict the onset of preeclampsia. Our high-sensitivity PlGF 1-2-3™ assay is optimized for first trimester screening of preeclampsia and is the only assay which was clinically validated by the ASPRE trial.
The same blood sample can be used for both preeclampsia and aneuploidy screening using the same instrument and markers; no additional blood sample is required.
In pregnancies that develop preeclampsia, maternal serum placental growth factor (PlGF) levels decrease significantly in the first trimester. This makes it an important biomarker used to predict the onset of preeclampsia. Our high-sensitivity PlGF 1-2-3™ assay is optimized for first trimester screening of preeclampsia and is the only assay which was clinically validated by the ASPRE trial.
The same blood sample can be used for both preeclampsia and aneuploidy screening using the same instrument and markers; no additional blood sample is required.
Combined screening model
Based on the evidence from research studies, international guidelines are recommending a combined screening program for preeclampsia at 11-13+6 weeks as the most effective way to identify women at high risk of pre-eclampsia in the early stages of pregnancy.
The combined screening program is made up of four simple steps that require short training and minimal additional investment in equipment. Our Lifecycle ™ software can generate a unique patient risk profile and report based on these combined screening markers.
- Medical history
- PlGF blood test
- Blood pressure
- Ultrasound (if available)
Based on the evidence from research studies, international guidelines are recommending a combined screening program for preeclampsia at 11-13+6 weeks as the most effective way to identify women at high risk of pre-eclampsia in the early stages of pregnancy.
The combined screening program is made up of four simple steps that require short training and minimal additional investment in equipment. Our Lifecycle ™ software can generate a unique patient risk profile and report based on these combined screening markers.
- Medical history
- PlGF blood test
- Blood pressure
- Ultrasound (if available)
2nd and 3rd trimester: PlGF as a single marker or sFlt-1/PlGF ratio
Women with signs or symptoms of preeclampsia do not always develop preeclampsia. Angiogenic markers can be used to help identify women with increased risk for developing preeclampsia in the coming days.
After 20 weeks of pregnancy PlGF and sFlt-1 are both predictive and diagnostic for preeclampsia. Determining serum PlGF concentration, used as a single marker, or sFlt-1 and PlGF, used as a ratio, improve the clinical management and decision making (risk stratification) with women showing signs and symptoms of preeclampsia.
PlGF alone and sFlt-1/PlGF ratio have comparable performance for preeclampsia rule-in and rule-out, and both options are equally recommended for clinical use. However, PLGF alone, with concentration-based cut-offs, could provide simpler and more affordable alternative to dual biomarker testing.
Using PlGF has additional advantages. Studies have shown that PlGF is a good marker (decreased serum PlGF level) for identifying pregnancies with placental insufficiency including fetal growth restriction and/or stillbirth.
Women with signs or symptoms of preeclampsia do not always develop preeclampsia. Angiogenic markers can be used to help identify women with increased risk for developing preeclampsia in the coming days.
After 20 weeks of pregnancy PlGF and sFlt-1 are both predictive and diagnostic for preeclampsia. Determining serum PlGF concentration, used as a single marker, or sFlt-1 and PlGF, used as a ratio, improve the clinical management and decision making (risk stratification) with women showing signs and symptoms of preeclampsia.
PlGF alone and sFlt-1/PlGF ratio have comparable performance for preeclampsia rule-in and rule-out, and both options are equally recommended for clinical use. However, PLGF alone, with concentration-based cut-offs, could provide simpler and more affordable alternative to dual biomarker testing.
Using PlGF has additional advantages. Studies have shown that PlGF is a good marker (decreased serum PlGF level) for identifying pregnancies with placental insufficiency including fetal growth restriction and/or stillbirth.
User configurable laboratory data management
Lifecycle™ software enables monitoring of preeclampsia status with PlGF concentration or the sFlt-1/PlGF ratio. The results can be linked to the patient case in Lifecycle™ software allowing the user to track samples and view all available results in one place. The assay cut-offs for preeclampsia management are user configurable and the software can be tailored to population.
Lifecycle™ software enables monitoring of preeclampsia status with PlGF concentration or the sFlt-1/PlGF ratio. The results can be linked to the patient case in Lifecycle™ software allowing the user to track samples and view all available results in one place. The assay cut-offs for preeclampsia management are user configurable and the software can be tailored to population.
Explore our biochemical prenatal & preeclampsia testing applications
Questions?
We’re here to help.
Contact us Please note that product labeling (such as kit insert, product label, and kit box) may be different compared to the company branding. Please contact your local representative for further details.